Fig. 1 · Structure

Documents & Downloads

MDA 19

Cat. No. A11939 CAS 1048973-47-2

CB2 agonist

MDA 19 is a potent and selective agonist for the cannabinoid receptor CB2, with reasonable selectivity over the psychoactive CB1 receptor.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
CHO EC50 63.4 nM Agonist activity at human CB2 receptor expressed in CHO cells by [35S]GTPgammaS assay [PMID: 18666769]
CHO EC50 867 nM Agonist activity at human CB1 receptor expressed in CHO cells by [35S]GTPgammaS assay [PMID: 18666769]

In Vitro Studies

MDA 19 had an IC50 for cell viability of 36.3 μM in M14 cells after 24 h of incubation. In Hep3B cells incubated for 48 h, the IC50 for cell proliferation was 56.69 μM. In U2OS cells treated for 72 h, concentrations higher than 20 µM produced cell viability lower than 50% compared with 0 µM. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cell viability in M14 cells

Cell-based study · M14 cells [1]

M14 cells were incubated with MDA 19 for 24 h. The IC50 for cell viability was 36.3 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
viability of M14 cellsIC50 36.3 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 1, 2, 4, 6, 8, 10, 20, 40, 60, 80, 100, and 200 μM
Exposure duration
24 h of incubation
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: MDA 19

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Dose-dependent assay (S2, S3); Results > MDA-19 inhibits melanoma cells in a dose-dependent manner (S34, S36)

viability of M14 cells: viability of M14 cells; comparator: 0 μM — Results > MDA-19 inhibits melanoma cells in a dose-dependent manner (S34, S36)

Cell proliferation in Hep3B cells

Cell-based study · Hep3B [2]

Hep3B cells were incubated with the compound for 48 h. The cell proliferation IC50 was 56.69 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell proliferationIC50 IC50 values were 56.69 μM[2]

Literature-Reported Treatment Conditions

Treatment concentration
0, 5, 10, 20, 30, 40, 50, 80, 100, and 120 μM
Exposure duration
for 48 h
Method
incubate with HCC cells
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: MDA 19

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Cells culture and treatment (S2); Methods > Dose-dependent assay (S17, S18); Results > MDA19 inhibited proliferation of HCC cells in a dose- and time-dependent manner (S51)

Cell proliferation: Cell proliferation; comparator: 0 μM — Methods > Dose-dependent assay (S18); Results > MDA19 inhibited proliferation of HCC cells in a dose- and time-dependent manner (S51)

Viability response in U2OS cells

Cell-based study · U2OS [3]

U2OS cells were treated with MDA 19 for 72 h. At concentrations higher than 20 µM, cell viability was lower than 50% compared with that at 0 µM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cells’ viability by measuring OD valuecell viability lower than 50%[3]

Literature-Reported Treatment Conditions

Treatment concentration
0, 1, 2.5, 5, 10, 20, 50, 100, 200 µM
Exposure duration
72 h
Method
cells were administrated with MDA19
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: MDA 19

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Cell proliferation assay (S16, S17); Results > Effect of MDA19 on proliferation of OS cells (S45, S46)

cells’ viability by measuring OD value: cells’ viability by measuring OD value; comparator: 0 µM — Results > Effect of MDA19 on proliferation of OS cells (S45, S46)

In Vivo Studies

Sprague–Dawley rats received MDA 19 intraperitoneally at 5–100 mg/kg. Treatment did not substitute for the discriminative effects of Δ9-THC, with < 20% drug-appropriate responding. [4]

Drug discrimination in Sprague–Dawley rats

Animal study · Sprague–Dawley; six rats [4]

Sprague–Dawley rats received MDA 19 intraperitoneally at 5–100 mg/kg. Treatment did not substitute for the discriminative effects of Δ9-THC, with < 20% drug-appropriate responding.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
percentage of total responses made on the drug-appropriate leverdrug-appropriate responding 5–100 mg/kg: < 20% drug-appropriate responding[4]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
30 min
Vehicle
ethanol/Cremophor EL/0.9% saline (ECS 1:1:18)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
MDA 19 5–100 mg/kgVehicle and Δ9-THC controlsMDA-19 did not substitute (< 20% drug-appropriate responding) for the discriminative effects of Δ9-THC[4]
MDA 19 5–100 mg/kg
Model: Sprague–Dawley; six rats
Methods and source locations

Compound reported in the paper: MDA 19

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Subjects (S1); Methods > Drugs (S9); Methods > Discrimination procedures (S34, S35, S36); Results > Drug discrimination (S103); Fig. 3 legend (S113)

percentage of total responses made on the drug-appropriate lever: percentage of total responses made on the drug-appropriate lever; comparator: Vehicle and Δ9-THC controls — Methods > Discrimination procedures (S36); Results > Drug discrimination (S103); Fig. 3 legend (S113)

MDA 19 5–100 mg/kg · Methods > Drugs (S9); Methods > Discrimination procedures (S36); Results > Drug discrimination (S103)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 1048973-47-2
Applications CB2 agonist
Formula C21H23N3O2
Molecular Weight 349.4
SMILES
CCCCCCN1C2=CC=CC=C2/C(=N/NC(=O)C3=CC=CC=C3)/C1=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Dang N, Meng X, Ma S, et al. MDA-19 Suppresses Progression of Melanoma Via Inhibiting the PI3K/Akt Pathway. Open Med (Wars) (2018). PMID: 30613786 DOI: 10.1515/med-2018-0061 Source material
  2. [2] Rao M, Chen D, Zhan P, et al. MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway. Biol Direct (2019). PMID: 31053086 DOI: 10.1186/s13062-019-0241-1 Source material
  3. [3] Liu B, Xu L, Dai EN, et al. Anti-tumoral potential of MDA19 in human osteosarcoma via suppressing PI3K/Akt/mTOR signaling pathway. Biosci Rep (2018). PMID: 30442873 DOI: 10.1042/BSR20181501 Source material
  4. [4] Shetty RA, Hill RD, McDonald JA, et al. Behavioral pharmacology of novel synthetic indazole, indole, and benzimidazole cannabinoids in rodents. J Cannabis Res (2026). PMID: 41526973 DOI: 10.1186/s42238-026-00390-3 Source material

Added to your cart

View Cart Checkout
Loading...